A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-22 and is reviewed periodically as new material appears.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
== History == β-Endorphin was discovered in camel pituitary extracts by C.H. Li and David Chung. The primary structure of β-endorphin was unknowingly determined 10 years earlier, when Li and colleagues analyzed the sequence of another neuropeptide produced in the pituitary gland, γ-lipotropin. They noticed that the C-terminus region of this neuropeptide was similar to that of some enkephalins, suggesting that it may have a similar function to these neuropeptides. The C-terminal sequence of γ-lipotropin turned out to be the primary sequence of the β-endorphin.
== Pharmacokinetics == Shortly after absorption via the small intestine, carindacillin is hydrolyzed into carbenicillin. Carbenicillin acts by interfering with final cell wall synthesis in susceptible bacteria, including Pseudomonas aeruginosa, Escherichia coli, and some Proteus. The most common adverse effects include nausea, bad taste, diarrhea, vomiting, flatulence, and glossitis. Carindacillin was approved for use in adults in the treatment of prostatitis and urinary tract infections. Dosing was between 2000 and 4000 mg daily, divided into equally spaced doses.
According to the new policy, Twitter verifies six different types of accounts; for three of them (companies, brands, and influential individuals like activists), the existence of a Wikipedia page will be one criterion for showing that the account has "Off Twitter Notability".
==== Australia ==== Taco Bell first opened in Australia in September 1981, but Taco Bell was ordered to change its name after the owner of a local restaurant successfully sued Taco Bell for misleading conduct. The local restaurant was called "Taco Bell's Casa" and had been operating in Australia since the 1970s. The owner successfully argued that Sydneysiders would confuse the takeaway chain with his restaurant, and this would damage his reputation. Taco Bell later opened in 1997 in Australia with a store in the cinema district on George Street, Sydney and a year later in 1998 within a few KFC stores in the state of New South Wales, but by 2005, the Taco Bell brand was pulled out of the country. On September 13, 2017, Collins Foods announced that Taco Bell would return to the Australian market, with their first store being situated in the Brisbane suburb of Annerley in Queensland using a refurbished Sizzler restaurant which had closed earlier that year. The Annerley store opened on November 4, 2017. In 2018, Collins Foods signed a development deal with Yum! Brands to open over 50 Taco Bell restaurants across Australia between January 2019 and December 2021. A legal dispute with Victoria-based restaurant chain Taco Bill was resolved in February 2020. As of February 2024, there are 39 Taco Bell restaurants across Australia; 12 in New South Wales, 13 in Queensland, nine in Victoria, and four in Western Australia. There are also plans to open restaurants in other locations, such as Canberra, the Central Coast, Port Macquarie and Toowoomba.
IGF-1, IGF receptors (IGF-1R) and IGF binding proteins (IGFBP). The therapeutic applications of IGF-1 are limited due to its poor central uptake and potential side-effects. IGF-1 that is not bound to its binding protein bears a very short half-life and is cleaved by enzymes to form the tripeptide glycine-proline-glutamate (GPE). However, the enzymatic instability of GPE, with a plasma half-life of less than 4 minutes, is further cleaved to produce the final product, cyclic-Glycine-Proline (cGP).
Sources: en.wikipedia.org
Encroachment on wildlife habitats. The construction of new villages and housing developments in rural areas force animals to live in dense populations, creating opportunities for microbes to mutate and emerge. Changes in agriculture. The introduction of new crops attracts new crop pests and the microbes they carry to farming communities, exposing people to unfamiliar diseases. The destruction of rain forests. As countries make use of their rain forests, by building roads through forests and clearing areas for settlement or commercial ventures, people encounter insects and other animals harboring previously unknown microorganisms. Uncontrolled urbanization. The rapid growth of cities in many developing countries tends to concentrate large numbers of people into crowded areas with poor sanitation. These conditions foster transmission of contagious diseases. Modern transport. Ships and other cargo carriers often harbor unintended "passengers", that can spread diseases to faraway destinations. While with international jet-airplane travel, people infected with a disease can carry it to distant lands, or home to their families, before their first symptoms appear.
==== Barack Obama ==== Hitchens supported Barack Obama in the 2008 presidential election. Hitchens criticized Obama's democratic opponent Hillary Clinton writing in a column for the slate "Indifferent to truth, willing to use police-state tactics and vulgar libels against inconvenient witnesses, hopeless on health care and flippant and fast and loose with national security: the case against Hillary Clinton for president is open-and-shut". In an article for Slate he stated, "I used to call myself a single-issue voter on the essential question of defending civilization against its terrorist enemies and their totalitarian protectors, and on that 'issue' I hope I can continue to expose and oppose any ambiguity." He was critical of both main party candidates, Obama and John McCain, but wrote that Obama would be the better choice. Hitchens went on to call McCain "senile", and his choice of running mate Sarah Palin "absurd", calling Palin a "pathological liar" and a "national disgrace". Hitchens also wrote that "Obama is greatly overrated" and that the Obama-Biden ticket "show[s] some signs of being able and willing to profit from experience".
Although often prevented and treatable if detected early, pressure ulcers can be very difficult to prevent in critically ill people, frail elders, and individuals with impaired mobility such as wheelchair users (especially where spinal injury is involved). Primary prevention is to redistribute pressure by regularly turning the person. The benefit of turning to avoid further sores is well documented since at least the 19th century. In addition to turning and re-positioning the person in the bed or wheelchair, eating a balanced diet with adequate protein and keeping the skin free from exposure to urine and stool is important. The rate of pressure ulcers in hospital settings is high; the prevalence in European hospitals ranges from 8.3% to 23%, and the prevalence was 26% in Canadian healthcare settings from 1990 to 2003. In 2013, there were 29,000 documented deaths from pressure ulcers globally, up from 14,000 deaths in 1990. The United States has tracked rates of pressure injury since the early 2000s. Whittington and Briones reported nationwide rates of pressure injuries in hospitals of 6% to 8%. By the early 2010s, one study showed the rate of pressure injury had dropped to about 4.5% across the Medicare population following the introduction of the International Guideline for pressure injury prevention. Padula and colleagues have witnessed a +29% uptick in pressure injury rates in recent years associated with the rollout of penalizing Medicare policies.
== About == CoWIN serves the function of registration, appointment scheduling, identity verification, vaccination and certification of each vaccinated member. Registration for the vaccination slots can be booked on the same day or a few days prior. The platform has also been integrated in the Aarogya Setu and UMANG Apps. The certificate after COVID-19 vaccination can also be obtained through the platform. To expedite the development of this platform, several existing digital assets were leveraged, such as: Electronic Vaccine Intelligence Network (eVIN), Digital Infrastructure for Vaccination Open Credentialing (DIVOC), DigiLocker, Surveillance and Action for Events Following Vaccination (SAFE-VAC). CoWIN application was developed with five modules: the orchestration module; the vaccination cold chain module; the citizen registration module; the vaccinator module; and the certificate, feedback, and adverse event following immunization reporting module. As of now, eight vaccines can be registered on the platform in the country Covishield (18+), Covaxin (15+), Corbevax (12-14), Sputnik V (18+), Corbevax (12-14), Gemcovac (18+) Incovacc (18+), ZyCoV-D (18+) and Covovax (12+). In the future, the Health ministry is working on upgrading CoWIN for the effective implementation of India's universal immunization programme. Co-WIN platform will be used for booking slots for the routine vaccinations like Polio and Hepatitis.
Morgan Freeman (born June 1, 1937) is an American actor, producer, and narrator. In a career spanning six decades, he has received numerous accolades, including an Academy Award and a Golden Globe Award, as well as a nomination for a Grammy Award and a Tony Award. He was honored with the Kennedy Center Honor in 2008, an AFI Life Achievement Award in 2011, the Cecil B. DeMille Award in 2012, and Screen Actors Guild Life Achievement Award in 2018. In a 2022 readers' poll by Empire, he was voted one of the 50 greatest actors of all time. Born in Memphis, Tennessee, Freeman was raised in Mississippi, where he began acting in school plays. He studied theater arts in Los Angeles and appeared in stage productions in his early career. He rose to fame in the 1970s for his role in the children's television series The Electric Company. Freeman then appeared in the Shakespearean plays Coriolanus and Julius Caesar, the former of which earned him an Obie Award. In 1978, he was nominated for the Tony Award for Best Featured Actor in a Play for his role as Zeke in the Richard Wesley play The Mighty Gents. Freeman received the Academy Award for Best Supporting Actor playing a former boxer in Clint Eastwood's sports drama Million Dollar Baby (2004). He was Oscar-nominated for Street Smart (1987), Driving Miss Daisy (1989), The Shawshank Redemption (1994), and Invictus (2009). He also performed in Glory (1989), Lean on Me (1989), Robin Hood: Prince of Thieves (1991), Unforgiven (1992), Se7en (1995), Amistad (1997), Deep Impact (1998), Gone Baby Gone (2007), and The Bucket List (2007).
Sources: en.wikipedia.org
==== TP0453 ==== TP0453 is a 287 amino acid protein associated with the inner membrane of the microbe's outer membrane. This protein lacks the extensive beta sheet structure that is characteristic of other membrane proteins, and does not traverse the outer membrane. This protein's function has been hypothesized to be involved with control of nutrient uptake.
=== Research Award (since 1986) === 2025 Tian (Autumn) Qiu 2024 Elizabeth K. Neumann 2023 Kelly Marie Hines and Stacy Malaker 2022 Gloria Sheynkman 2021 Xin Yan 2019 Eleanor Browne 2014 Kerri A. Pratt 2013 Yu Xia 2012 Ileana M. Cristea and Sharon J. Pitteri 2011 Judit Villen 2010 Sarah Trimpin 2007 Rebecca Jockusch 2006 Heather Desaire 2005 Kristina Hăkansson 2004 Lingjun Li 2003 Andrea Grottoli 2001 Deborah S. Gross 2000 Elaine Marzluff 1998 Mary T. Rodgers 1997 M. Judith Charles 1994 Kimberly A. Prather 1993 Susan Graul 1992 Vicki H. Wysocki 1991 Hilkka I. Kenttämaa 1990 Jennifer Brodbelt 1987 Susan Olesik
== Adverse effects == The most widely reported side effect of glycyrrhizin use via consumption of black liquorice is reduction of blood potassium levels, which can affect body fluid balance and function of nerves. Chronic consumption of black licorice, even in moderate amounts, is associated with an increase in blood pressure, may cause irregular heart rhythm, and may have adverse interactions with prescription drugs. In extreme cases, death can occur as a result of excess consumption.
=== Manufacturing === In 2017, the total output (gross value added) in the manufacturing industry amounted to 14.4% of total output in Denmark. 325,000 people or a little less than 12% of all employed persons worked in manufacturing (including utilities, mining and quarrying) in 2016. Main sub-industries are manufacture of pharmaceuticals, machinery, and food products.
=== Dual-flow === Dual-flow, also known as dual, countercurrent chromatography occurs when both phases are flowing in opposite directions inside the column. Instruments are available for dual-flow operation for both Hydrodynamic and hydrostatic CCC. Dual-flow countercurrent chromatography was first described by Yoichiro Ito in 1985 for foam CCC where gas-liquid separations were performed. Liquid–liquid separations soon followed. The countercurrent chromatography instrument must be modified so that both ends of the column have both inlet and outlet capabilities. This mode may accommodate continuous or sequential separations with the sample being introduced in the middle of the column or between two bobbins in a hydrodynamic instrument. A technique called intermittent countercurrent extraction (ICcE) is a quasi-continuous method where the flow of the phases is alternated "intermittently" between normal and reversed-phase elution so that the stationary phase also alternates.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.